Changes in the vaginal microbiota following antibiotic treatment for Mycoplasma genitalium, Chlamydia trachomatis and bacterial vaginosis.
Adolescent
Adult
Anti-Bacterial Agents
/ pharmacology
Chlamydia Infections
/ drug therapy
Chlamydia trachomatis
/ drug effects
Female
Gardnerella vaginalis
/ drug effects
Gram-Positive Bacterial Infections
/ drug therapy
Humans
Microbiota
/ drug effects
Middle Aged
Mycoplasma Infections
/ drug therapy
Mycoplasma genitalium
/ drug effects
Vagina
/ drug effects
Vaginosis, Bacterial
/ drug therapy
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
02
2020
accepted:
28
06
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
18
9
2020
Statut:
epublish
Résumé
The human vagina harbor a rich microbiota. The optimal state is dominated by lactobacilli that help to maintain health and prevent various diseases. However, the microbiota may rapidly change to a polymicrobial state that has been linked to a number of diseases. In the present study, the temporal changes of the vaginal microbiota in patients treated for sexually transmitted diseases or bacterial vaginosis (BV) and in untreated controls were studied for 26 days. The patients included 52 women treated with azithromycin, tetracyclines or moxifloxacin for present or suspected infection with Chlamydia trachomatis or Mycoplasma genitalium. Women with concurrent BV were also treated with metronidazole. The controls were 10 healthy women of matching age. The microbiota was analyzed by 16S rRNA gene deep sequencing, specific qPCRs and microscopy. There was generally good correlation between Nugent score and community state type (CST) and qPCR confirmed the sequencing results. By sequencing, more than 600 different taxa were found, but only 33 constituted more than 1 ‰ of the sequences. In both patients and controls the microbiota could be divided into three different community state types, CST-I, CST-III and CST-IV. Without metronidazole, the microbiota remained relatively stable regarding CST although changes were seen during menstrual periods. Administration of metronidazole changed the microbiota from CST-IV to CST-III in approximately 50% of the treated patients. In contrast, the CST was generally unaffected by azithromycin or tetracyclines. In 30% of the BV patients, Gardnerella vaginalis was not eradicated by metronidazole. The majority of women colonized with Ureaplasma parvum remained positive after azithromycin while U. urealyticum was eradicated.
Identifiants
pubmed: 32722712
doi: 10.1371/journal.pone.0236036
pii: PONE-D-20-04151
pmc: PMC7386580
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236036Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Obstet Gynecol. 2019 May;220(5):476.e1-476.e11
pubmed: 30707966
Sci Rep. 2019 May 23;9(1):7750
pubmed: 31123296
Clin Transl Gastroenterol. 2018 Jun 19;9(6):161
pubmed: 29915224
J Clin Microbiol. 2007 Mar;45(3):1016-8
pubmed: 17202272
Int J STD AIDS. 2016 Oct;27(11):928-37
pubmed: 27147267
J Clin Microbiol. 1991 Feb;29(2):297-301
pubmed: 1706728
J Antimicrob Chemother. 2015 Nov;70(11):3134-40
pubmed: 26283670
mBio. 2019 Aug 13;10(4):
pubmed: 31409678
Am J Epidemiol. 2017 Jul 15;186(2):194-201
pubmed: 28472225
Clin Infect Dis. 2003 Mar 1;36(5):663-8
pubmed: 12594649
Clin Infect Dis. 2020 Feb 14;70(5):811-813
pubmed: 30972414
Am J Med. 1983 Jan;74(1):14-22
pubmed: 6600371
mBio. 2013 Aug 06;4(4):
pubmed: 23919998
Hum Reprod. 2019 Jun 4;34(6):1042-1054
pubmed: 31119299
PLoS One. 2016 Jun 08;11(6):e0157046
pubmed: 27276347
Int J STD AIDS. 2018 Nov;29(13):1258-1272
pubmed: 30049258
J Infect Dis. 2006 Jun 1;193(11):1478-86
pubmed: 16652274
Sci Transl Med. 2012 May 2;4(132):132ra52
pubmed: 22553250
JAMA Dermatol. 2017 Sep 1;153(9):897-905
pubmed: 28538949
Hum Reprod. 2016 Apr;31(4):795-803
pubmed: 26911864
PLoS One. 2018 Jan 24;13(1):e0191625
pubmed: 29364944
Sex Transm Infect. 2008 Dec;84(7):546-7
pubmed: 18653564
Clin Infect Dis. 2019 May 2;68(10):1675-1683
pubmed: 30407498
Am J Obstet Gynecol. 2013 Dec;209(6):505-23
pubmed: 23659989
J Clin Microbiol. 2004 Feb;42(2):683-92
pubmed: 14766837
J Clin Microbiol. 2007 Sep;45(9):3145
pubmed: 17652481
Clin Microbiol Rev. 2016 Apr;29(2):223-38
pubmed: 26864580
PLoS One. 2019 Apr 4;14(4):e0214425
pubmed: 30946763
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28827422
Liver Int. 2013 Oct;33(9):1309-15
pubmed: 23763259
PLoS One. 2012;7(11):e49506
pubmed: 23185346
BMC Infect Dis. 2013 Oct 16;13:480
pubmed: 24131550
Front Microbiol. 2019 Aug 13;10:1890
pubmed: 31456791
Antimicrob Agents Chemother. 2015 Oct 12;60(1):52-6
pubmed: 26459899
PLoS One. 2014 Jul 21;9(7):e102743
pubmed: 25047036
mSystems. 2019 Jun 4;4(4):
pubmed: 31164450
Am J Obstet Gynecol. 1986 Jan;154(1):120-6
pubmed: 3511702
Trends Microbiol. 2019 Feb;27(2):105-117
pubmed: 30497919
PLoS One. 2014 May 07;9(5):e96659
pubmed: 24805362
J Infect Dis. 2015 Sep 1;212(5):793-802
pubmed: 25676470
Anaerobe. 2019 Apr;56:61-65
pubmed: 30753898
BMJ. 1999 Jul 24;319(7204):220-3
pubmed: 10417083
Am J Obstet Gynecol. 2020 Feb;222(2):157.e1-157.e13
pubmed: 31404542
PLoS One. 2010 Apr 15;5(4):e10197
pubmed: 20419168